{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:36:22Z","timestamp":1768084582805,"version":"3.49.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40265-013-0108-1","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T14:00:51Z","timestamp":1378216851000},"page":"1431-1450","source":"Crossref","is-referenced-by-count":46,"title":["HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy"],"prefix":"10.1007","volume":"73","author":[{"given":"Giovanni","family":"Guaraldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Stentarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Zona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,4]]},"reference":[{"issue":"9377","key":"108_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","volume":"362","author":"A Mocroft","year":"2003","unstructured":"Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D\u2019Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22\u20139.","journal-title":"Lancet"},{"issue":"13","key":"108_CR2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"108_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","volume":"300","author":"K Bhaskaran","year":"2008","unstructured":"Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51\u20139.","journal-title":"JAMA"},{"issue":"7","key":"108_CR4","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51\u20138.","journal-title":"AIDS"},{"issue":"3","key":"108_CR5","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","volume":"14","author":"A Carr","year":"2000","unstructured":"Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(3):F25\u201332.","journal-title":"AIDS"},{"issue":"6","key":"108_CR6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ajcn\/69.6.1162","volume":"69","author":"ES Engelson","year":"1999","unstructured":"Engelson ES, Kotler DP, Tan Y, Agin D, Wang J, Pierson RN Jr, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr. 1999;69(6):1162\u20139.","journal-title":"Am J Clin Nutr"},{"issue":"9106","key":"108_CR7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(97)11518-5","volume":"351","author":"KD Miller","year":"1998","unstructured":"Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351(9106):871\u20135.","journal-title":"Lancet"},{"issue":"1","key":"108_CR8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1743-7075-1-12","volume":"1","author":"ES Freedland","year":"2004","unstructured":"Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (Lond). 2004;1(1):12.","journal-title":"Nutr Metab (Lond)"},{"issue":"7","key":"108_CR9","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1210\/jc.2004-2431","volume":"90","author":"A Vigano","year":"2005","unstructured":"Vigano A, Mora S, Manzoni P, Schneider L, Beretta S, Molinaro M, et al. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents. J Clin Endocrinol Metab. 2005;90(7):4075\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"108_CR10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1586\/14787210.3.5.727","volume":"3","author":"MT Yin","year":"2005","unstructured":"Yin MT, Glesby MJ. Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity. Expert Rev Anti Infect Ther. 2005;3(5):727\u201338.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"9106","key":"108_CR11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(97)11443-X","volume":"351","author":"JC Lo","year":"1998","unstructured":"Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. \u201cBuffalo hump\u201d in men with HIV-1 infection. Lancet. 1998;351(9106):867\u201370.","journal-title":"Lancet"},{"issue":"1","key":"108_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/514639","volume":"27","author":"VR Roth","year":"1998","unstructured":"Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 1998;27(1):65\u20137.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"108_CR13","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-199912030-00023","volume":"13","author":"RA Torres","year":"1999","unstructured":"Torres RA, Unger KW, Cadman JA, Kassous JY. Recombinant human growth hormone improves truncal adiposity and \u2018buffalo humps\u2019 in HIV-positive patients on HAART. AIDS. 1999;13(17):2479\u201381.","journal-title":"AIDS"},{"issue":"9170","key":"108_CR14","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A Carr","year":"1999","unstructured":"Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093\u20139.","journal-title":"Lancet"},{"issue":"4","key":"108_CR15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-199903110-00004","volume":"13","author":"C Gervasoni","year":"1999","unstructured":"Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Musicco M, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13(4):465\u201371.","journal-title":"AIDS"},{"issue":"3","key":"108_CR16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1468-1293.2001.00073.x","volume":"2","author":"VM Carter","year":"2001","unstructured":"Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2(3):174\u201380.","journal-title":"HIV Med"},{"issue":"2","key":"108_CR17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","volume":"40","author":"P Bacchetti","year":"2005","unstructured":"Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40(2):121\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"108_CR18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","volume":"32","author":"KA Lichtenstein","year":"2003","unstructured":"Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32(1):48\u201356.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"108_CR19","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/jac\/dki062","volume":"55","author":"A Martin","year":"2005","unstructured":"Martin A, Mallon PW. Therapeutic approaches to combating lipoatrophy: do they work? J Antimicrob Chemother. 2005;55(5):612\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"108_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2334-5-80","volume":"5","author":"G Parruti","year":"2005","unstructured":"Parruti G, Toro GM. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report. BMC Infect Dis. 2005;5:80.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"108_CR21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1310\/hct0906-407","volume":"9","author":"E Ribera","year":"2008","unstructured":"Ribera E, Paradineiro JC, Curran A, Sauleda S, Garcia-Arumi E, Castella E, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials. 2008;9(6):407\u201317.","journal-title":"HIV Clin Trials"},{"issue":"18","key":"108_CR22","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","volume":"360","author":"MM Kitahata","year":"2009","unstructured":"Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"108_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1468-1293.2007.00537.x","volume":"9","author":"A Nguyen","year":"2008","unstructured":"Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000\u20132006. HIV Med. 2008;9(3):142\u201350.","journal-title":"HIV Med"},{"issue":"4","key":"108_CR24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/QAI.0b013e318158c0a6","volume":"46","author":"E Mutimura","year":"2007","unstructured":"Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46(4):451\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"108_CR25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0b013e31819c16f4","volume":"51","author":"S Mercier","year":"2009","unstructured":"Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr. 2009;51(2):224\u201330.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"15","key":"108_CR26","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1097\/00002030-200010200-00025","volume":"14","author":"J Miller","year":"2000","unstructured":"Miller J, Carr A, Smith D, Emery S, Law MG, Grey P, et al. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS. 2000;14(15):2406\u20137.","journal-title":"AIDS"},{"issue":"9256","key":"108_CR27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","volume":"357","author":"E Martinez","year":"2001","unstructured":"Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357(9256):592\u20138.","journal-title":"Lancet"},{"issue":"5","key":"108_CR28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/01.qai.0000229996.75116.da","volume":"42","author":"Study of Fat R, Metabolic Change in HIVI","year":"2006","unstructured":"Study of Fat R, Metabolic Change in HIVI. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42(5):562\u201371.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"108_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QAI.0b013e31816d9ba1","volume":"48","author":"D Wohl","year":"2008","unstructured":"Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr. 2008;48(1):44\u201352.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"108_CR30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e31814b94e2","volume":"46","author":"C Grunfeld","year":"2007","unstructured":"Grunfeld C, Rimland D, Gibert CL, Powderly WG, Sidney S, Shlipak MG, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr. 2007;46(3):283\u201390.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"108_CR31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","volume":"15","author":"KA Lichtenstein","year":"2001","unstructured":"Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15(11):1389\u201398.","journal-title":"AIDS"},{"issue":"14","key":"108_CR32","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","volume":"12","author":"K Brinkman","year":"1998","unstructured":"Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12(14):1735\u201344.","journal-title":"AIDS"},{"issue":"10","key":"108_CR33","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/383573","volume":"38","author":"J Blanch","year":"2004","unstructured":"Blanch J, Rousaud A, Martinez E, De Lazzari E, Milinkovic A, Peri JM, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis. 2004;38(10):1464\u201370.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"108_CR34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00126334-200212010-00006","volume":"31","author":"J Blanch","year":"2002","unstructured":"Blanch J, Rousaud A, Martinez E, De Lazzari E, Peri JM, Milinkovic A, et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2002;31(4):404\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"108_CR35","first-page":"546","volume":"10","author":"E Collins","year":"2000","unstructured":"Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10(9):546\u201350.","journal-title":"AIDS Read"},{"issue":"7","key":"108_CR36","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","volume":"18","author":"A Martin","year":"2004","unstructured":"Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2\u00a0years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18(7):1029\u201336.","journal-title":"AIDS"},{"issue":"2","key":"108_CR37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","volume":"38","author":"GA McComsey","year":"2004","unstructured":"McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38(2):263\u201370.","journal-title":"Clin Infect Dis"},{"issue":"16","key":"108_CR38","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","volume":"20","author":"GJ Moyle","year":"2006","unstructured":"Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043\u201350.","journal-title":"AIDS"},{"issue":"2","key":"108_CR39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.qai.0000147527.64863.1a","volume":"38","author":"PW Mallon","year":"2005","unstructured":"Mallon PW, Wand H, Law M, Miller J, Cooper DA, Carr A, et al. Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J Acquir Immune Defic Syndr. 2005;38(2):156\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"108_CR40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/135965350801300309","volume":"13","author":"Q He","year":"2008","unstructured":"He Q, Engelson ES, Ionescu G, Glesby MJ, Albu JB, Kotler DP. Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. Antivir Ther. 2008;13(3):423\u20138.","journal-title":"Antivir Ther"},{"issue":"13","key":"108_CR41","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1097\/QAD.0b013e32833c055a","volume":"24","author":"J Lo","year":"2010","unstructured":"Lo J, Abbara S, Rocha-Filho JA, Shturman L, Wei J, Grinspoon SK. Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS. 2010;24(13):2127\u201330.","journal-title":"AIDS"},{"issue":"1","key":"108_CR42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ajcn\/86.1.100","volume":"86","author":"JB Albu","year":"2007","unstructured":"Albu JB, Kenya S, He Q, Wainwright M, Berk ES, Heshka S, et al. Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr. 2007;86(1):100\u20136.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"108_CR43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1152\/japplphysiol.00797.2005","volume":"100","author":"M Torriani","year":"2006","unstructured":"Torriani M, Thomas BJ, Barlow RB, Librizzi J, Dolan S, Grinspoon S. Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution. J Appl Physiol. 2006;100(2):609\u201314.","journal-title":"J Appl Physiol"},{"issue":"5","key":"108_CR44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molmed.2010.03.002","volume":"16","author":"M Caron-Debarle","year":"2010","unstructured":"Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med. 2010;16(5):218\u201329.","journal-title":"Trends Mol Med"},{"issue":"12","key":"108_CR45","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/oxfordjournals.aje.a010167","volume":"151","author":"CE Lewis","year":"2000","unstructured":"Lewis CE, Jacobs DR Jr, McCreath H, Kiefe CI, Schreiner PJ, Smith DE, et al. Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol. 2000;151(12):1172\u201381.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"108_CR46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11908-005-0050-9","volume":"7","author":"V Appay","year":"2005","unstructured":"Appay V, Boutboul F, Autran B. The HIV infection and immune activation: \u201cto fight and burn\u201d. Curr Infect Dis Rep. 2005;7(6):473\u20139.","journal-title":"Curr Infect Dis Rep"},{"issue":"1","key":"108_CR47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/135965350801300103","volume":"13","author":"M Caron","year":"2008","unstructured":"Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther. 2008;13(1):27\u201338.","journal-title":"Antivir Ther"},{"issue":"35","key":"108_CR48","doi-asserted-by":"crossref","first-page":"13857","DOI":"10.1073\/pnas.0706529104","volume":"104","author":"SG Clarke","year":"2007","unstructured":"Clarke SG. HIV protease inhibitors and nuclear lamin processing: getting the right bells and whistles. Proc Natl Acad Sci USA. 2007;104(35):13857\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"108_CR49","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.0704212104","volume":"104","author":"C Coffinier","year":"2007","unstructured":"Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, et al. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci USA. 2007;104(33):13432\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"108_CR50","doi-asserted-by":"crossref","first-page":"9797","DOI":"10.1074\/jbc.M709629200","volume":"283","author":"C Coffinier","year":"2008","unstructured":"Coffinier C, Hudon SE, Lee R, Farber EA, Nobumori C, Miner JH, et al. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem. 2008;283(15):9797\u2013804.","journal-title":"J Biol Chem"},{"key":"108_CR51","unstructured":"http:\/\/www.idf.org\/webdata\/docs\/MetSyndrome_FINAL.pdf . Accessed 13 Mar 2013."},{"key":"108_CR52","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486\u201397.","DOI":"10.1001\/jama.285.19.2486"},{"issue":"3","key":"108_CR53","first-page":"152","volume":"10","author":"G Guaraldi","year":"2008","unstructured":"Guaraldi G, Murri R, Orlando G, Squillace N, Stentarelli C, Zona S, et al. Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev. 2008;10(3):152\u201361.","journal-title":"AIDS Rev"},{"issue":"6","key":"108_CR54","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1086\/381684","volume":"38","author":"FJ Palella Jr","year":"2004","unstructured":"Palella FJ Jr, Cole SR, Chmiel JS, Riddler SA, Visscher B, Dobs A, et al. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. Clin Infect Dis. 2004;38(6):903\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"108_CR55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11136-005-8342-y","volume":"15","author":"G Guaraldi","year":"2006","unstructured":"Guaraldi G, Orlando G, Murri R, Vandelli M, De Paola M, Beghetto B, et al. Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire. Qual Life Res. 2006;15(1):173\u20138.","journal-title":"Qual Life Res"},{"issue":"3","key":"108_CR56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.mco.0000165010.31826.3d","volume":"8","author":"LD Plank","year":"2005","unstructured":"Plank LD. Dual-energy X-ray absorptiometry and body composition. Curr Opin Clin Nutr Metab Care. 2005;8(3):305\u20139.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"2","key":"108_CR57","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QAI.0b013e31815b0792","volume":"47","author":"T Joy","year":"2008","unstructured":"Joy T, Keogh HM, Hadigan C, Dolan SE, Fitch K, Liebau J, et al. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008;47(2):174\u201384.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"108_CR58","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/oby.2011.393","volume":"20","author":"S Kaul","year":"2012","unstructured":"Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD, et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring). 2012;20(6):1313\u20138.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"108_CR59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ajcn\/57.4.470","volume":"57","author":"R Ross","year":"1993","unstructured":"Ross R, Shaw KD, Martel Y, de Guise J, Avruch L. Adipose tissue distribution measured by magnetic resonance imaging in obese women. Am J Clin Nutr. 1993;57(4):470\u20135.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"108_CR60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1152\/jappl.1992.72.2.787","volume":"72","author":"R Ross","year":"1992","unstructured":"Ross R, Leger L, Morris D, de Guise J, Guardo R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol. 1992;72(2):787\u201395.","journal-title":"J Appl Physiol"},{"key":"108_CR61","first-page":"177","volume":"60","author":"R Ross","year":"1993","unstructured":"Ross R, Shaw KD, Martel Y, de Guise J, Hudson R, Avruch L. Determination of total and regional adipose tissue distribution by magnetic resonance imaging in android women. Basic Life Sci. 1993;60:177\u201380.","journal-title":"Basic Life Sci"},{"issue":"8","key":"108_CR62","first-page":"543","volume":"16","author":"RS Koester","year":"1992","unstructured":"Koester RS, Hunter GR, Snyder S, Khaled MA, Berland LL. Estimation of computerized tomography derived abdominal fat distribution. Int J Obes Relat Metab Disord. 1992;16(8):543\u201354.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"10","key":"108_CR63","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.ijo.0802398","volume":"27","author":"KH Liu","year":"2003","unstructured":"Liu KH, Chan YL, Chan WB, Kong WL, Kong MO, Chan JC. Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. Int J Obes Relat Metab Disord. 2003;27(10):1267\u201373.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"8","key":"108_CR64","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0022-2275(20)40090-2","volume":"35","author":"N Abate","year":"1994","unstructured":"Abate N, Burns D, Peshock RM, Garg A, Grundy SM. Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res. 1994;35(8):1490\u20136.","journal-title":"J Lipid Res"},{"issue":"2","key":"108_CR65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/oby.2004.32","volume":"12","author":"Q He","year":"2004","unstructured":"He Q, Engelson ES, Wang J, Kenya S, Ionescu G, Heymsfield SB, et al. Validation of an elliptical anthropometric model to estimate visceral compartment area. Obes Res. 2004;12(2):250\u20137.","journal-title":"Obes Res"},{"issue":"1","key":"108_CR66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02668185","volume":"14","author":"GZ Yang","year":"2002","unstructured":"Yang GZ, Myerson S, Chabat F, Pennell DJ, Firmin DN. Automatic MRI adipose tissue mapping using overlapping mosaics. MAGMA. 2002;14(1):39\u201344.","journal-title":"MAGMA"},{"issue":"8","key":"108_CR67","first-page":"347","volume":"7","author":"LW Poll","year":"2002","unstructured":"Poll LW, Wittsack HJ, Koch JA, Willers R, Scherer A, Kapitza C, et al. Quantification of total abdominal fat volumes using magnetic resonance imaging. Eur J Med Res. 2002;7(8):347\u201352.","journal-title":"Eur J Med Res"},{"issue":"2","key":"108_CR68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jocd.2010.01.005","volume":"13","author":"P Freitas","year":"2010","unstructured":"Freitas P, Santos AC, Carvalho D, Pereira J, Marques R, Martinez E, et al. Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy. J Clin Densitom. 2010;13(2):197\u2013203.","journal-title":"J Clin Densitom"},{"key":"108_CR69","doi-asserted-by":"crossref","unstructured":"O\u2019Neil T, Ross R, Zona S, Orlando G, Carli F, Garlassi E, et al. Combined use of waist and thigh circumference to identify high-risk, abdominally obese HIV+ patients. J Int AIDS Soc Abstract Supplement n P37, pag 43, 11th International Congress on Drug Therapy in HIV infection, 11-15 Nov 2012, Glasgow, UK. 2012.","DOI":"10.7448\/IAS.15.6.18302"},{"issue":"8","key":"108_CR70","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2337\/diabetes.53.8.2087","volume":"53","author":"DB Carr","year":"2004","unstructured":"Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53(8):2087\u201394.","journal-title":"Diabetes"},{"issue":"2","key":"108_CR71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.atherosclerosis.2009.10.023","volume":"209","author":"MD Marques","year":"2010","unstructured":"Marques MD, Santos RD, Parga JR, Rocha-Filho JA, Quaglia LA, Miname MH, et al. Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis. 2010;209(2):481\u20136.","journal-title":"Atherosclerosis"},{"issue":"3","key":"108_CR72","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","volume":"4","author":"J Miller","year":"2003","unstructured":"Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4(3):293\u2013301.","journal-title":"HIV Med"},{"issue":"4","key":"108_CR73","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/COH.0b013e3281e72ca0","volume":"2","author":"PW Mallon","year":"2007","unstructured":"Mallon PW. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies. Curr Opin HIV AIDS. 2007;2(4):282\u201392.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"108_CR74","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/COH.0b013e3281e38a98","volume":"2","author":"SI Leuven van","year":"2007","unstructured":"van Leuven SI, Sankatsing RR, Vermeulen JN, Kastelein JJ, Reiss P, Stroes ES. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart! Curr Opin HIV AIDS. 2007;2(4):324\u201331.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"108_CR75","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/339866","volume":"34","author":"M Saves","year":"2002","unstructured":"Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34(10):1396\u2013405.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"108_CR76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/135965350901400203","volume":"14","author":"A Calmy","year":"2009","unstructured":"Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther. 2009;14(2):165\u201379.","journal-title":"Antivir Ther"},{"issue":"9868","key":"108_CR77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48\u00a0week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735\u201343.","journal-title":"Lancet"},{"key":"108_CR78","unstructured":"http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf . Accessed 7 July 2013."},{"key":"108_CR79","unstructured":"http:\/\/www.europeanaidsclinicalsociety.org\/images\/stories\/EACS-Pdf\/EACSGuidelines-v6.0-English.pdf . Accessed 7 July 2013."},{"issue":"3","key":"108_CR80","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","volume":"53","author":"JM Molina","year":"2010","unstructured":"Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323\u201332.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"108_CR81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","volume":"42","author":"JG Jemsek","year":"2006","unstructured":"Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42(2):273\u201380.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"108_CR82","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/597776","volume":"48","author":"G McComsey","year":"2009","unstructured":"McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clin Infect Dis. 2009;48(9):1323\u20136.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"108_CR83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/cir324","volume":"53","author":"GA McComsey","year":"2011","unstructured":"McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224\u00a0s. Clin Infect Dis. 2011;53(2):185\u201396.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"108_CR84","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1468-1293.2011.00941.x","volume":"12","author":"SM Vrouenraets","year":"2011","unstructured":"Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, et al. Randomized comparison of metabolic and renal effects of saquinavir\/r or atazanavir\/r plus tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients. HIV Med. 2011;12(10):620\u201331.","journal-title":"HIV Med"},{"issue":"13","key":"108_CR85","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","volume":"23","author":"AM Mills","year":"2009","unstructured":"Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679\u201388.","journal-title":"AIDS"},{"issue":"10","key":"108_CR86","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1089\/aid.2011.0327","volume":"28","author":"JA Aberg","year":"2012","unstructured":"Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, et al. Metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir in treatment-naive, HIV type 1-infected subjects over 48\u00a0weeks. AIDS Res Hum Retrovir. 2012;28(10):1184\u201395.","journal-title":"AIDS Res Hum Retrovir"},{"key":"108_CR87","doi-asserted-by":"crossref","unstructured":"Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al.; STARTMRK Investigators. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses [Erratum appears in J Acquir Immune Defic Syndr. 2011;58(4):e120]. J Acquir Immune Defic Syndr. 2010;55(1):39\u201348.","DOI":"10.1097\/QAI.0b013e3181da1287"},{"issue":"8","key":"108_CR88","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","volume":"53","author":"JK Rockstroh","year":"2011","unstructured":"Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807\u201316.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"108_CR89","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/aid.2011.0275","volume":"29","author":"J Reynes","year":"2013","unstructured":"Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, et al. Lopinavir\/ritonavir combined with raltegravir or tenofovir\/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retrovir. 2013;29(2):256\u201365.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"17","key":"108_CR90","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0b013e328315a7a5","volume":"22","author":"A Carr","year":"2008","unstructured":"Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, et al. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS. 2008;22(17):2313\u201321.","journal-title":"AIDS"},{"issue":"2","key":"108_CR91","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1128\/AAC.01662-12","volume":"57","author":"V Joly","year":"2013","unstructured":"Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, et al. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother. 2013;57(2):758\u201365.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"108_CR92","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/135965350300800403","volume":"8","author":"JP Lalezari","year":"2003","unstructured":"Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, et al. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther. 2003;8(4):279\u201387.","journal-title":"Antivir Ther"},{"issue":"2","key":"108_CR93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","volume":"12","author":"J Lunzen van","year":"2012","unstructured":"van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48\u00a0week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"108_CR94","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","volume":"62","author":"A Mills","year":"2013","unstructured":"Mills A, Mildvan D, Podzamczer D, Fatkenheuer G, Leal M, Than S, et al. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr. 2013;62(2):164\u201370.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"108_CR95","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","volume":"201","author":"DA Cooper","year":"2010","unstructured":"Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201(6):803\u201313.","journal-title":"J Infect Dis"},{"issue":"6","key":"108_CR96","first-page":"18250","volume":"15","author":"JM Molina","year":"2012","unstructured":"Molina JM, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M. Rilpivirine efficacy, virology and safety in ARV treatment-naive patients with viral load<\/=100,000 HIV-1 RNA c\/mL: ECHO and THRIVE 96-week results. J Int AIDS Soc. 2012;15(6):18250.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"108_CR97","first-page":"18221","volume":"15","author":"C Cohen","year":"2012","unstructured":"Cohen C, Wohl D, Arribas J, Henry K, Van Lunzen J, Bloch M, et al. STAR Study: single tablet regimen emtricitabine\/rilpivirine\/tenofovir DF is non-inferior to efavirenz\/emtricitabine\/tenofovir DF in ART-naive adults. J Int AIDS Soc. 2012;15(6):18221.","journal-title":"J Int AIDS Soc"},{"key":"108_CR98","doi-asserted-by":"crossref","unstructured":"Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C et al.; ECHO, THRIVE study groups. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6):939\u201350.","DOI":"10.1097\/QAD.0b013e32835cee6e"},{"issue":"9787","key":"108_CR99","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","volume":"378","author":"JM Molina","year":"2011","unstructured":"Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238\u201346.","journal-title":"Lancet"},{"issue":"9787","key":"108_CR100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","volume":"378","author":"CJ Cohen","year":"2011","unstructured":"Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229\u201337.","journal-title":"Lancet"},{"issue":"1","key":"108_CR101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/QAD.0b013e32833032ed","volume":"24","author":"AL Pozniak","year":"2010","unstructured":"Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24(1):55\u201365.","journal-title":"AIDS"},{"key":"108_CR102","doi-asserted-by":"crossref","unstructured":"Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr. 2013;62(2):171\u20139.","DOI":"10.1097\/QAI.0b013e31827a2ba2."},{"issue":"2","key":"108_CR103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/QAI.0b013e31827a2ba2.","volume":"62","author":"P Vernazza","year":"2013","unstructured":"Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr. 2013;62(2):171\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"108_CR104","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/dkr533","volume":"67","author":"G Fatkenheuer","year":"2012","unstructured":"Fatkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, et al. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother. 2012;67(3):685\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"108_CR105","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jir505","volume":"204","author":"PE Sax","year":"2011","unstructured":"Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir\/lamivudine versus tenofovir DF\/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191\u2013201.","journal-title":"J Infect Dis"},{"issue":"7","key":"108_CR106","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-154-7-201104050-00316","volume":"154","author":"ES Daar","year":"2011","unstructured":"Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445\u201356.","journal-title":"Ann Intern Med"},{"issue":"7","key":"108_CR107","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1086\/656363","volume":"51","author":"RL Puls","year":"2010","unstructured":"Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010;51(7):855\u201364.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"108_CR108","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/QAD.0b013e32834b4d48","volume":"25","author":"R Elion","year":"2011","unstructured":"Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine\/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25(15):1881\u20136.","journal-title":"AIDS"},{"issue":"9835","key":"108_CR109","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","volume":"379","author":"PE Sax","year":"2012","unstructured":"Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48\u00a0weeks. Lancet. 2012;379(9835):2439\u201348.","journal-title":"Lancet"},{"issue":"9835","key":"108_CR110","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"E DeJesus","year":"2012","unstructured":"DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429\u201338.","journal-title":"Lancet"},{"key":"108_CR111","doi-asserted-by":"crossref","unstructured":"Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S et al.; GS-236-0103 Study Team. A randomized, double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5):483\u20136.","DOI":"10.1097\/QAI.0b013e318286415c"},{"issue":"6","key":"108_CR112","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","volume":"25","author":"C Cohen","year":"2011","unstructured":"Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25(6):F7\u201312.","journal-title":"AIDS"},{"key":"108_CR113","doi-asserted-by":"crossref","unstructured":"Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D et al.; GS US-236-0102 Study Team. A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96\u2013100.","DOI":"10.1097\/QAI.0b013e318289545c"},{"key":"108_CR114","first-page":"531","volume":"7","author":"C Bernardini","year":"2013","unstructured":"Bernardini C, Maggiolo F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera\/Eviplera) in the treatment of HIV infection. Patient Prefer Adherence. 2013;7:531\u201342.","journal-title":"Patient Prefer Adherence"},{"key":"108_CR115","unstructured":"Moyle G, Hardy H, Hu W, Yang R, Wirtz V, DeGrosky M, et al. Incidence of hypertriglyceridemic waist (HTW) phenotype in a randomized prospective trial comparing atazanavir\/ritonavir (ATV\/r) and lopinavir\/ritonavir (LPV\/r) each in combination with tenofovir DF\/emtricitabine (TDF\/FTC) in antiretroviral naive HIV-1 infected subjects, a sub-study of CASTLE. In: 14th International workshop on co-morbidities and adverse drug reactions (IWCADR), 19\u201321 July 2012, Washington. 2012."},{"issue":"4","key":"108_CR116","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3851\/IMP2083","volume":"17","author":"GJ Moyle","year":"2012","unstructured":"Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A, Salvato P, Bogner JR, et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther. 2012;17(4):689\u2013700.","journal-title":"Antivir Ther"},{"issue":"11","key":"108_CR117","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/QAD.0b013e32832ba904","volume":"23","author":"TL Stanley","year":"2009","unstructured":"Stanley TL, Joy T, Hadigan CM, Liebau JG, Makimura H, Chen CY, et al. Effects of switching from lopinavir\/ritonavir to atazanavir\/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS. 2009;23(11):1349\u201357.","journal-title":"AIDS"},{"issue":"4","key":"108_CR118","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/QAD.0b013e32834f3507","volume":"26","author":"A Curran","year":"2012","unstructured":"Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26(4):475\u201381.","journal-title":"AIDS"},{"issue":"9","key":"108_CR119","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1089\/apc.2012.0135","volume":"26","author":"JE Lake","year":"2012","unstructured":"Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, et al. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012;26(9):532\u201340.","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"108_CR120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-1293.2010.00845.x","volume":"12","author":"DA Cooper","year":"2011","unstructured":"Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O\u2019Hearn M, et al. The effects of enfuvirtide therapy on body composition and metabolic parameters over 48\u00a0weeks in the TORO body imaging substudy. HIV Med. 2011;12(1):31\u20139.","journal-title":"HIV Med"},{"issue":"8","key":"108_CR121","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1468-1293.2012.01004.x","volume":"13","author":"MA Valantin","year":"2012","unstructured":"Valantin MA, Kolta S, Flandre P, Algarte Genin M, Meynard JL, Ponscarme D, et al. Body fat distribution in HIV-infected patients treated for 96\u00a0weeks with darunavir\/ritonavir monotherapy versus darunavir\/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy. HIV Med. 2012;13(8):505\u201315.","journal-title":"HIV Med"},{"key":"108_CR122","unstructured":"Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, et al. Impact of switching to darunavir\/ritonavir monotherapy vs. triple-therapy on Body fat redistribution and bone mass in virologically suppressed HIV-infected adults. The MONARCH randomized controlled trial. European AIDS Conference, Belgrade, Serbia, October 2011 [abstr PE75\/4]. 2011."},{"issue":"10","key":"108_CR123","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1089\/aid.2011.0336","volume":"28","author":"I Ofotokun","year":"2012","unstructured":"Ofotokun I, Sheth AN, Sanford SE, Easley KA, Shenvi N, White K, et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir\/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retrovir. 2012;28(10):1196\u2013206.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"3","key":"108_CR124","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"JE Gallant","year":"2006","unstructured":"Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"108_CR125","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","volume":"43","author":"AL Pozniak","year":"2006","unstructured":"Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine\/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes\u2014a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535\u201340.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"108_CR126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1310\/hct0806-381","volume":"8","author":"JR Madruga","year":"2007","unstructured":"Madruga JR, Cassetti I, Suleiman JM, Etzel A, Zhong L, Holmes CB, et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials. 2007;8(6):381\u201390.","journal-title":"HIV Clin Trials"},{"issue":"5","key":"108_CR127","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","volume":"51","author":"M Fisher","year":"2009","unstructured":"Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, et al. A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51(5):562\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"108_CR128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","volume":"198","author":"DW Cameron","year":"2008","unstructured":"Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198(2):234\u201340.","journal-title":"J Infect Dis"},{"issue":"1","key":"108_CR129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157016211794582687","volume":"9","author":"S Kolta","year":"2011","unstructured":"Kolta S, Flandre P, Van PN, Cohen-Codar I, Valantin MA, Pintado C, et al. Fat tissue distribution changes in HIV-infected patients treated with lopinavir\/ritonavir. Results of the MONARK trial. Curr HIV Res. 2011;9(1):31\u20139.","journal-title":"Curr HIV Res"},{"issue":"11","key":"108_CR130","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/jac\/dkq327","volume":"65","author":"JL Meynard","year":"2010","unstructured":"Meynard JL, Bouteloup V, Landman R, Bonnard P, Baillat V, Cabie A, et al. Lopinavir\/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother. 2010;65(11):2436\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"108_CR131","doi-asserted-by":"crossref","unstructured":"Bernardino JI, Pulido F, Martinez E, Arrizabalaga J, Domingo P, Portilla J et al.; GESIDA-6008-KRETA Study Group. Switching to lopinavir\/ritonavir with or without abacavir\/lamivudine in lipoatrophic patients treated with zidovudine\/abacavir\/lamivudine. J Antimicrob Chemother. 2013;68(6):1373\u201381.","DOI":"10.1093\/jac\/dks540"},{"issue":"3","key":"108_CR132","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.aids.0000200531.48866.3d","volume":"20","author":"E Martinez","year":"2006","unstructured":"Martinez E, Milinkovic A, Bianchi L, Gatell JM. Considerations about the value of sonography for the measurement of regional body fat. AIDS. 2006;20(3):465\u20136.","journal-title":"AIDS"},{"key":"108_CR133","doi-asserted-by":"crossref","unstructured":"Cavalcanti RB, Cheung AM, Raboud J, Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. J Clin Densitom. 2005 Fall;8(3):293\u20137.","DOI":"10.1385\/JCD:8:3:293"},{"issue":"11","key":"108_CR134","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/QAD.0b013e32834884e6","volume":"25","author":"R Scherzer","year":"2011","unstructured":"Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS. 2011;25(11):1405\u201314.","journal-title":"AIDS"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0108-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0108-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0108-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:27:46Z","timestamp":1715959666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0108-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":134,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0108-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}